Patient P-01663

Synthetic patientNBL-101 · Day 108 · 35–44 · M · baseline S14Open companion preview

Therapy response

Declining

Tolerance

Deteriorating

GI state

Deteriorating

Inflammatory state

Stable

Nutritional resilience

Declining

Discontinuation risk

66%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 No meaningful change — Dietary Support Protocol NP-02
Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 51 SC-12 recommended — Supportive Compound SC-12
Day 52 Patient accepted — Started SC-12 in the companion
Day 58 GI-04 recommended — GI Support Protocol GI-04
Day 58 GI symptom burden −17% vs expected — Supportive Compound SC-12
Day 59 Patient accepted — Started GI-04 in the companion
Day 64 Tolerance state changed — Unstable → Improving
Day 67 GI symptom burden −30% vs expected — GI Support Protocol GI-04
Day 73 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 47.

Primary contributors, last 14 days

Nutritional resilience-11
GI instability+9
Toxicity+5
Treatment adherence-3

What helped?

Dietary Support Protocol NP-02Day 31
Result: no meaningful change
Supportive Compound SC-12Day 51
Result: symptom burden −17%
GI Support Protocol GI-04Day 58
Result: symptom burden −30%

LIFE OS recommendation

Monitoring Escalation ME-01

82%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 42
- WearableHRV 23 ms, trending down
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 39/100
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
Autonomic recovery ↓25
- WearableResting HR 85 bpm
Drug metabolism and exposure ↑20
- BloodToxicity index 41

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 3 · butyrate capacity 39/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 28 ms
Sleep: 7.4 h
Steps: 7,873
Resting HR: 79 bpm

Daily log: GI score 39, nutritional resilience 46, adherence 53.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Log the daily check-in; one line is enough
Keep the current walking rhythm
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
No additional supplements this week
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01574	54%	S14	GI-04	improved	47
P-01649	51%	S14	GI-04	improved	46
P-01611	49%	S14	GI-04	improved	44
P-01534	48%	S14	GI-04	improved	50
P-01323	47%	S14	GI-04	improved	50
P-01490	47%	S05	GI-04	improved	51
P-01667	47%	S10	GI-04	improved	49
P-01674	47%	S14	GI-04	improved	48
P-01688	46%	S01	GI-04	improved	40
P-01705	46%	S14	GI-04	improved	39
P-01325	45%	S16	GI-04	improved	54
P-01431	45%	S14	GI-04	improved	41